6 Best Peptides for Peripheral Neuropathy

What to Know Before Choosing a Peptide for Peripheral Neuropathy

Peripheral neuropathy covers a wide range of conditions: the burning feet of diabetic nerve damage, the numbness that follows chemotherapy, the diffuse pain of small fiber neuropathy, and the slow loss of sensation after traumatic nerve injury. The peptides people use for these conditions are just as varied, and so is the evidence behind them. Some have completed placebo-controlled human trials. Others have only been tested in animal models. A few have nothing beyond community-reported use. All of them appear in this guide because the inclusion criterion is straightforward: a compound earns a slot if people use it or are actively discussing using it for peripheral neuropathy. Evidence strength shapes how each option is described; it is never a reason to leave a compound off the list.

FDA-approved, telemedicine-prescribed, and research-only compounds are all represented here. That breadth matters because the conventional treatments for neuropathy, including gabapentin, pregabalin, and duloxetine, manage pain but do not promote nerve regeneration. The peptide conversation exists largely because people are looking for something that might address the underlying nerve damage rather than just modulate the signal.

The entries are numbered by how prominently each compound appears in the research and in real-world documented use, not as a recommendation of one over another. The first entry is the peptide that shows up most prominently when you survey the clinical landscape and the community forums together. The right choice depends on the subtype of neuropathy involved, the evidence level a person requires, and what they are building with the help of a healthcare provider or the MyPeptidePal app.

1. ARA-290: The Strongest Human Trial Record in This Category

ARA-290, also called Cibinetide in clinical literature, is the peptide with the most developed human trial record for peripheral neuropathy, and it earned that position through deliberate engineering. It is a non-erythropoietic analog of erythropoietin, designed to carry all of EPO's tissue-protective effects without the blood-thickening cardiovascular risks that make traditional EPO dangerous outside of anemia treatment. The receptor it targets is called the Innate Repair Receptor, a distinct heterodimer that, when activated, triggers nerve fiber regeneration and neuroinflammation reduction rather than red blood cell production.

The human trial data is the most substantial for any peptide in this neuropathy category. In a placebo-controlled Phase II trial in small fiber neuropathy, participants showed measurable increases in intraepidermal nerve fiber density over 28 days. That is regrowth of small sensory fibers, observed and quantified in a controlled setting. A separate Phase II trial in people with Type 2 diabetes and peripheral neuropathy found the compound safe, with no significant adverse events and no meaningful changes in kidney, liver, or blood parameters. ARA-290 currently holds FDA Fast Track designation and Orphan Drug designation for neuropathic pain associated with sarcoidosis, and it is actively entering Phase III trials.

Community reports from people with small fiber neuropathy and related conditions broadly align with the trial findings. Users describe substantial pain reductions, with onset typically in the first one to two weeks. The pattern that comes up most consistently is that the relief is real but not permanent: pain tends to return after stopping, and some users find that continuous use leads to diminishing returns, pointing toward cycling or washout periods as a practical consideration. The best-responder profile, both from trials and from community observation, appears to be people with autoimmune small fiber neuropathy or conditions involving central sensitization.

The current limitation is access. ARA-290 is not available through standard telemedicine for general use as of 2026. Legitimate access runs through clinical trial enrollment or expanded access programs. For people outside that window, this is a compound to watch closely as Phase III data develops.

2. BPC-157: The Most Studied Peptide for Axonal Regeneration in Animal Models

BPC-157, short for Body Protection Compound-157, is the peptide most commonly reached for in community protocols for nerve damage, and that popularity rests on a preclinical evidence base that is genuinely robust, even though it has not yet extended to human trials for peripheral neuropathy. It is a synthetic 15-amino acid peptide derived from a protein sequence found in human gastric juice, and it acts through multiple pathways at once, which is part of why it appears across so many different healing contexts.

For nerve repair specifically, the primary mechanism involves FAK-Schwann cell signaling. Schwann cells are the specialized cells that wrap peripheral nerves in myelin, the insulating sheath that allows electrical signals to travel efficiently. When nerves are damaged, Schwann cells are critical to the regeneration process, and BPC-157 appears to activate the signaling pathways that drive their involvement in axonal regrowth. Alongside that, it upregulates VEGF to promote angiogenesis, the formation of new blood vessels that supply recovering nerve tissue with oxygen and nutrients. It also activates the MAPK/ERK pathway, which governs how cells reorganize their internal structure during repair. Animal studies using sciatic nerve transection models have shown axonal regrowth, reduced inflammation, and restored sensory function after BPC-157 administration.

No human clinical trials have examined BPC-157 for peripheral neuropathy as of 2026. What exists beyond the animal studies is niche practitioner data and a substantial body of user-reported experience describing reductions in burning sensations, tingling, and numbness. In community protocols it is frequently paired with TB-500, on the reasoning that the two compounds address complementary aspects of nerve repair. Whether that combination produces better outcomes than either alone has not been tested in controlled research.

BPC-157 is not FDA-approved for any human therapeutic use and is classified as a research chemical. It is prohibited by WADA for competitive athletes. The animal research is encouraging enough to anchor the community conversation, but anyone using it operates with the human trial gap clearly in view.

3. TB-500: The Standard Companion Peptide in Nerve Repair Protocols

TB-500 is the research chemical form of Thymosin Beta-4, a naturally occurring 43-amino acid peptide found throughout the body. It rarely appears alone in neuropathy discussions; it is almost always mentioned as a partner to BPC-157, and understanding why requires a look at what it does differently.

Where BPC-157 focuses on regenerative signaling in damaged nerve tissue, TB-500 works primarily through Schwann cell biology and cell migration. Schwann cells do not simply wait at the injury site; they migrate toward damaged axons, clear debris left by Wallerian degeneration (the process by which the segment of a nerve beyond an injury site breaks down), and create the structural environment that axon regrowth requires. TB-500 supports that migration and reduces the ongoing inflammatory response that slows the repair process. The two compounds address different phases of the same recovery sequence, which is the rationale behind pairing them.

The evidence for TB-500 in peripheral neuropathy is preclinical. No human clinical trial data has been published for this compound in this condition as of 2026. The animal data supports a role in nerve repair, and the mechanistic logic behind the BPC-157 pairing is coherent, but the clinical record does not yet exist. In community protocols, TB-500 appears as a consistent second element in nerve repair stacks rather than as a standalone choice. Like BPC-157, it is a research chemical not cleared for telemedicine prescription, and its use outside clinical trials is self-directed.

4. Cerebrolysin: A Neurotrophic Preparation With Decades of International Use

Cerebrolysin is different in character from the single-molecule peptides on this list. It is a complex mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine brain proteins, and it has been used clinically for decades in European, Russian, and Asian markets for neurological conditions including stroke, traumatic brain injury, and dementia. That clinical history gives it a different standing than a research chemical, even though the evidence specifically for peripheral neuropathy is limited.

Its mechanism involves mimicking endogenous neurotrophic factors, the signaling proteins like NGF and BDNF that govern neuronal survival, growth, and differentiation. Neurotrophic factors are the nervous system's primary tools for maintaining and repairing itself, and Cerebrolysin's mixture of neuropeptides appears to provide multiple simultaneous neurotrophic signals. It also supports Schwann cell survival and function, connecting it to the peripheral nerve repair biology that BPC-157 addresses through a different pathway. Animal studies have shown early neuroplasticity effects, and its international clinical track record for central nervous system conditions is well established.

For peripheral neuropathy specifically, it has not been established as a proven treatment in humans. Its record is in central nervous system conditions rather than peripheral nerve damage, and no robust trials focused specifically on peripheral neuropathy have been published. In community discussions about nerve damage, Cerebrolysin appears among people exploring neurotrophin-based approaches, often used alongside other compounds, on the logic that broad neurotrophic support should have some relevance to peripheral nerve repair. That logic is biologically coherent; the specific clinical validation for this use is not yet there.

Cerebrolysin is available in some countries as a prescription preparation, typically given by intravenous infusion or intramuscular injection. It is not FDA-approved for peripheral neuropathy or nerve regeneration in the United States.

5. Humanin: Mitochondrial Cytoprotection for Neuropathy With a Metabolic Component

Humanin is a 21-amino acid peptide encoded in the mitochondrial genome, specifically in the 16S rRNA region, placing it in the class of mitochondria-derived peptides. These are peptides the mitochondria produce to regulate their own survival and to signal stress states to surrounding cells. That origin is directly relevant to certain types of neuropathy.

In chemotherapy-induced peripheral neuropathy and metabolic neuropathy, one of the central mechanisms of nerve damage is mitochondrial dysfunction. Chemotherapy drugs generate reactive oxygen species that fragment mitochondria inside nerve cells. When mitochondria fragment, axons shorten and lose their ability to conduct signals. Research at the University of Illinois at Chicago has specifically identified this mitochondrial fission process as a driver of axonal shortening in neuropathy. Humanin acts as a cytoprotective peptide within this context: it inhibits neuronal cell death pathways, preserves mitochondrial function in stressed nerve cells, and activates survival signaling that keeps neurons viable under metabolic stress. Its closely related counterpart among mitochondria-derived peptides, MOTS-c, addresses similar mitochondrial biology through AMPK activation and appears alongside Humanin in research discussions of this mechanism.

The evidence here is at the mechanistic research stage. No human clinical trial has been published for Humanin in peripheral neuropathy as of 2026. The biological rationale connecting mitochondrial cytoprotection to axonal survival in chemotherapy-induced and metabolic neuropathy is established; the step from that rationale to a validated human treatment has not been taken. Humanin appears more often in research contexts and advanced biohacker discussions about mitochondrial health than in mainstream community protocols. Its relevance is most clearly focused on neuropathy subtypes where mitochondrial dysfunction is a central driver.

6. Cortagen: Neural Bioregulator From the Russian Peptide Research Tradition

Cortagen is a tetrapeptide, four amino acids, belonging to the class of peptide bioregulators developed primarily in Russian research institutions. The bioregulator class is built around short peptides theorized to regulate gene expression in specific target tissues by binding to gene promoter regions and modulating protein synthesis. Cortagen's designated target tissue is neural, and it appears in protocols aimed at supporting nervous system repair, though its development and evidence base come largely from Eastern European clinical settings rather than Western randomized controlled trial programs.

No published human clinical trial data for Cortagen in peripheral neuropathy appears in the Western research literature as of 2026. The evidence is experiential by Western standards. Russian and Eastern European bioregulator research has generated a body of work on this compound class, but that literature has limited visibility in databases like PubMed and the trial designs often do not meet the methodological standards Western evidence-based medicine requires. What exists in community discussions is use within broader peptide bioregulator protocols, typically by people who have explored the Russian bioregulator tradition specifically and are incorporating Cortagen as part of a comprehensive neural support approach.

One distinction worth stating clearly: Cortagen (the tetrapeptide bioregulator) is not the same compound as Cortistatin, a separate neuropeptide that works through somatostatin receptors and ghrelin receptors to inhibit pain transmission in spinal cord neurons. The similarity in names causes confusion in community discussions, but they have different structures, different mechanisms, and different evidence bases. Cortistatin has its own emerging research literature in neuropathic pain; Cortagen is the bioregulator with the thinner Western evidence record. If you encounter both names in research, they refer to different compounds.

Cortagen is available as a research chemical or supplement in some markets and is not FDA-approved for any therapeutic indication.

How These Peptides Compare

Frequently Asked Questions

Is ARA-290 available to buy outside of clinical trials?

ARA-290 is not available through standard telemedicine channels for general use as of 2026. Access runs primarily through clinical trial enrollment or expanded access programs for qualifying conditions such as sarcoidosis-associated neuropathic pain. Some community members source it through international research chemical suppliers, which carries the quality and purity concerns typical of unregulated channels. The compound's active Phase III development means legitimate clinical access may expand as trial data matures.

Do any of these peptides have FDA approval for peripheral neuropathy?

No peptide currently holds FDA approval specifically for treating peripheral neuropathy. ARA-290 has FDA Fast Track and Orphan Drug designations for neuropathic pain in sarcoidosis, which signals regulatory interest but is not an approval. The medications approved for managing neuropathy symptoms, including gabapentin, pregabalin, and duloxetine, are conventional drugs rather than peptides. All of the peptides in this guide are used off-label, through clinical trials, or as research chemicals.

What is the difference between symptom relief and nerve regeneration?

Conventional neuropathy treatments like gabapentin and pregabalin work by modulating pain signals in the nervous system; they reduce the sensation of pain without addressing the underlying nerve damage. Peptides like ARA-290 and BPC-157 are studied for their potential to promote structural repair, including measurable increases in nerve fiber density observed in ARA-290 trials. Whether a given peptide primarily addresses symptoms or structural regeneration depends on its mechanism and the evidence behind it, and the two goals are not mutually exclusive.

Why do most of these peptides have animal data but no human trials?

Running human clinical trials for peripheral neuropathy is costly and methodologically challenging, partly because neuropathy is a heterogeneous condition with different causes, subtypes, and severity levels that complicate outcome measurement. Most peptide compounds in this space are in early-stage research, and animal models such as sciatic nerve transection are a standard first step before progressing to human trials. The gap between a promising animal study and a completed Phase II human trial typically involves years of additional safety and dosing work that most of these compounds have not yet undergone.

Is combining multiple peptides from this list a common practice?

Combining peptides is common in community protocols, with the BPC-157 and TB-500 pairing being the most frequently discussed for nerve repair. The rationale is that the two compounds address complementary phases of the regeneration process, though this combination has not been tested in controlled research. Some community members have also paired ARA-290 with BPC-157 or with GHK-Cu. Whether any combination produces better outcomes than a single compound used alone remains an open question without controlled data to answer it.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for peripheral neuropathy in one place.